Perioperative and Conventionally Timed Chemotherapy in Operable Breast Cancer

  • A. Goldhirsch
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 98)


Adjuvant chemotherapy with CMF in pathological stage II breast cancer has been shown by the Milan Group to produce a disease-free survival and overall survival advantage at 6 years in premenopausal patients (Bonadonna et al. 1978). The value of adjuvant chemotherapy in postmenopausal patients is less well established, although it seems likely to be real. It has been suggested that treatment success may well be dose related in all patients (Bonadonna and Valagussa 1981) and toxicity related (Carpenter et al. 1982). The role of adjuvant chemotherapy in node-negative patients has still to be confirmed (Senn et al. 1981).


Breast Cancer Adjuvant Chemotherapy Operable Breast Cancer Premenopausal Patient Patient Accrual 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:20–51CrossRefGoogle Scholar
  2. Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450–464PubMedGoogle Scholar
  3. Bonadonna G, Rossi A, Tancini G, Brambilla C, Marchini S, Valagussa P, Veronesi U (1981) Adjuvant treatment for breast cancer. The Milan Institute experience. Proceed was of the 3rd international conference on the adjuvant therapy of cancer. March 18–21, TucsonGoogle Scholar
  4. Carpenter TT, Maddox WA, Laws HL, Wirtschaften DD, Soong SJ (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer 50:18–23PubMedCrossRefGoogle Scholar
  5. Deacon R, Lumb M, Perry J (1980) Inactivation of methionine syntetase by nitrous oxide. Eur J Biochem 104:419–422PubMedCrossRefGoogle Scholar
  6. DeWys WD (1972) Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32:374–379PubMedGoogle Scholar
  7. Dudman NPB, Slowiaczek P, Tattersall MHN (1982) Methotrexate rescue by 5-methyl THF or 5-formyl THF in lymphoblastoid cell lines. Cancer Res 42:502–507PubMedGoogle Scholar
  8. Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528–534PubMedGoogle Scholar
  9. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Fischer G, Lippman M, Savlov E, Wittliff J, Fischer ER (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6PubMedCrossRefGoogle Scholar
  10. Goldie JH, Coldman AJ (1979) A mathematic model of relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733PubMedGoogle Scholar
  11. Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, Be Banne SM (1980) Antiestrogen, cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer; a preliminary report. Surgery 87:494–501PubMedGoogle Scholar
  12. Jungi WF, Brunner KW, Cavalli F, Martz G, Rosset G, Barrelet L (1981) Short or long term adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 22:435 (Abstract C399)Google Scholar
  13. Kano Y, Sakamoto S, Sakuraya K, Kuboto T, Hida K, Suda K, Takaku F (1981) Effect of nitrous oxide on human bone marrow cells and its synergistic effect with methionine and methotrexate on functional folate deficiency. Cancer Res 41:4698–4701PubMedGoogle Scholar
  14. Ludwig Breast Cancer Study Group (1983) Severe toxicity encountered in adjuvant combination chemotherapy for breast cancer administered in the immediate post-mastectomy period. Lancet II:542–544CrossRefGoogle Scholar
  15. Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T (1978) Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088–2098PubMedCrossRefGoogle Scholar
  16. Nunn JF, Sharer NM, Gorchein A, Jones JA, Wickramasingha SN (1982) Megaloblastic haemopoiesis after multiple short term exposure to nitrous oxide. Lancet I:1379–1381CrossRefGoogle Scholar
  17. Schabel FM (1977) Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40:558–568PubMedCrossRefGoogle Scholar
  18. Senn HJ, Jungi WF, Amgwerd R (1981) Chemoimmunotherapy with LMF plus BCG in node-positive and node-positive breast cancer. In: Adjuvant therapy for cancer III. Salmon SE, Jones SE (eds). Grune and Stratton, New York, 385–390Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • A. Goldhirsch
    • 1
  1. 1.Ludwig Institut für Krebsforschung, InselspitalBernSwitzerland

Personalised recommendations